Recent Updates
Recently added Catalysts
ANIK Negative Sentiment Score: 30/100

ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating potential claims against Anika Therapeutics, focusing on whether the company has violated federal securities laws or engaged in unlawful business practices. The investigation follows a significant drop in Anika's stock price, which fell 27.42% after the release of trial results indicating that their product Hyalofast did not meet its expected clinical endpoints. The firm encourages affected stockholders to discuss their legal rights and options.

Market Sentiment Analysis

CONCERNS & RISKS

  • Anika's stock price fell by 27.42% following the disappointing trial results.
  • The clinical trial did not meet its pre-specified co-primary endpoints.
  • Increased subject dropout rates and missed visits during COVID complicated the study's data.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Anika and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK) on behalf of Anika stockholders. Our investigation concerns whether Anika has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
On July 30, 2025, Anika issued a press release "announc[ing] topline results from its U.S. pivotal clinical trial of Hyalofast, a resorbable, hyaluronic acid scaffold used in conjunction with autologous bone marrow aspirate concentrate (BMAC) for cartilage repair." The press release stated that "[w]hile Hyalofast demonstrated consistent improvements in treated patients across all measures of pain and function relative to microfracture, the study did not meet its pre-specified co-primary endpoints. The study was likely impacted by both a higher subject dropout rate in the microfracture arm and missed visits during COVID. This resulted in missing data, which reduced the evaluable sample size and complicated the statistical analysis."
On this news, Anika's stock price fell $3.06 per share, or 27.42%, to close at $8.10 per share on July 30, 2025.
If you purchased or otherwise acquired Anika shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What should Anika investors do if they suffered losses?

Investors who lost money in Anika should contact Brandon Walker or Marion Passmore.

What is the concern regarding Anika Therapeutics?

The investigation focuses on potential violations of federal securities laws by Anika.

How did Anika's stock react to recent news?

Anika's stock dropped 27.42% to $8.10 per share after negative trial results.

Is there a cost to discuss claims with Bragar Eagel & Squire?

There is no cost or obligation to discuss potential claims with the law firm.

Where can I find more information about Bragar Eagel & Squire?

More information can be found on their website at www.bespc.com.

Last updated: Oct 9, 2025